Skip to main content

Advertisement

SpringerLink
Log in

Residual symptoms and disease burden among patients with psoriatic arthritis: is a new disease activity index required?

  • Observational Research
  • Published:
Rheumatology International Aims and scope Submit manuscript

Abstract

The aim of this study was to investigate residual symptoms or disease burden among patients with psoriatic arthritis (PsA) in remission or low disease activity (LDA) according to different outcome measures. A total of 126 patients with PsA were included and the following variables were assessed: Tender joint count (TJC), swollen joint count (SJC), patient’s global assessment, physician’s global assessment, pain, extra-articular manifestations, Psoriasis Area and Severity Index, Health Assessment Questionnaire, fatigue, Short Form-36, psoriatic quality of life, Hospital Anxiety and Depression Scale and C-reactive protein (CRP). Disease activity was measured using three different outcome measures including minimal disease activity (MDA), disease activity score for 28 joints (DAS28-CRP) and disease activity in psoriatic arthritis (DAPSA). The number (%) of patients who achieved remission or LDA was 9(14.1), 34(27.0) and 67(53.2) according to MDA, DAPSA and DAS28-CRP criteria, respectively, under usual care. SJC > 1 was seen in 3(8.8%) and 13(19.4%) of patients in remission or LDA as defined by the DAPSA and DAS28-CRP respectively. TJC > 1 was found at least 32.4% of patients with PsA in remission or LDA by any definition. 22.2–49.3% of patients with PsA in remission or LDA still suffered from clinically important fatigue. No patients in MDA had a substantial functional impairment while 2.9–19.4% of patients fulfilling remission or LDA according to the DAPSA and DAS28-CRP experienced functional disability. At least 22.2% of patients with PsA in remission or LDA by any description had higher risk for depression, and at least 11.1% for anxiety. Despite patients with PsA in remission or LDA by various definition, they may continue to experience pain, tender or swollen joints, fatigue, physiologic distress as well as functional impairment suggesting that there is a significant unmet need with regard to definition of remission or LDA in PsA.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Gladman DD, Antoni C, Mease P, Clegg DO, Nash P (2005) Psoriatic arthritis: epidemiology, clinical features, course, and outcome. Ann Rheum Dis 64(suppl 2):14–17. https://doi.org/10.1136/ard.2004.032482

    Article  Google Scholar 

  2. Nas K, Karkucak M, Durmus B, Karatay S, Capkin E, Kaya A, Ucmak D, Akar ZA, Cevik R, Kilic E, Kilic G, Ozgocmen S (2015) Comorbidities in patients with psoriatic arthritis: a comparison with rheumatoid arthritis and psoriasis. Int J Rheum Dis 18:873–879. https://doi.org/10.1111/1756-185X.12580

    Article  PubMed  Google Scholar 

  3. Grigor C, Capell H, Stirling A, McMahon AD, Lock P, Vallance R, Kincaid W, Porter D (2004) Effect of a treatment strategy of tight control for rheumatoid arthritis (the TICORA study): a single-blind randomised controlled trial. Lancet 364:263–269. https://doi.org/10.1016/S0140-6736(04)16676-2

    Article  PubMed  Google Scholar 

  4. Stoffer MA, Schoels MM, Smolen JS, Aletaha D, Breedveld FC, Burmester G, Bykerk V, Dougados M, Emery P, Haraoui B, Gomez-Reino J, Kvien TK, Nash P, Navarro-Compan V, Scholte-Voshaar M, van Vollenhoven R, van der Heijde D, Stamm TA (2016) Evidence for treating rheumatoid arthritis to target: results of a systematic literature search update. Ann Rheum Dis 75:16–22. https://doi.org/10.1136/annrheumdis-2015-207526

    Article  PubMed  Google Scholar 

  5. Coates LC, Moverley AR, McParland L, Brown S, Navarro-Coy N, O’Dwyer JL, Meads DM, Emery P, Conaghan PG, Helliwell PS (2015) Effect of tight control of inflammation in early psoriatic arthritis (TICOPA): a UK multicentre, open-label, randomised controlled trial. Lancet 386:2489–2498. https://doi.org/10.1016/S0140-6736(15)00347-5

    Article  PubMed  PubMed Central  Google Scholar 

  6. Smolen JS, Schols M, Braun J, Dougados M, FitzGerald O, Gladman DD, Kavanaugh A, Landewe R, Mease P, Sieper J, Stamm T, Wit M, Aletaha D, Baraliakos X, Betteridge N, Bosch FVD, Coates LC, Emery P, Gensler LS, Gossec L, Helliwell P, Jongkees M, Kvien TK, Inman RD, McInnes IB, Maccarone M, Machado PM, Molto A, Ogdie A, Poddubnyy D, Ritchlin C, Rudwaleit M, Tanew A, Thio B, Veale D, Vlam K, van der Heijde D (2018) Treating axial spondyloarthritis and peripheral spondyloarthritis, especially psoriatic arthritis, to target: 2017 update of recommendations by an international task force. Ann Rheum Dis 77:3–17. https://doi.org/10.1136/annrheumdis-2017-211734

    Article  PubMed  Google Scholar 

  7. Nas K, Kilic E, Cevik R, Bodur H, Ataman S, Ayhan F, Akgul O, Akinci A, Altay Z, Capkin E, Dagli AZ, Duruoz T, Gurer G, Gogus F, Garip Y, Kacar C, Kamanli A, Kaptanoglu E, Kaya T, Kocabas H, Ozdemirel EA, Ozel S, Sezer I, Sunar I, Yilmaz G (2018) Management of psoriatic arthritis: Turkish League Against Rheumatism (TLAR) Expert Opinions. Arch Rheum 33:108–127. https://doi.org/10.5606/ArchRheumatol.2018.6946

    Article  Google Scholar 

  8. Gossec L, Smolen JS, Ramiro S, de Wit M, Cutolo M, Dougados M, Emery P, Landewe R, Oliver S, Aletaha D, Betteridge N, Braun J, Burmester G, Canete JD, Damjanov N, FitzGerald O, Haglund E, Helliwell P, Kvien TK, Lories R, Luger T, Maccarone M, Marzo-Ortega H, McGonagle D, McInnes IB, Olivieri I, Pavelka K, Schett G, Sieper J, van den Bosch F, Veale DJ, Wollenhaupt J, Zink A, van der Heijde D (2016) European League Against Rheumatism (EULAR) recommendations for the management of psoriatic arthritis with pharmacological therapies: 2015 update. Ann Rheum Dis 75:499–510. https://doi.org/10.1136/annrheumdis-2015-208337

    Article  CAS  Google Scholar 

  9. Coates LC, Kavanaugh A, Mease PJ, Soriano ER, Laura Acosta-Felquer M, Armstrong AW, Bautista-Molano W, Boehncke WH, Campbell W, Cauli A, Espinoza LR, FitzGerald O, Gladman DD, Gottlieb A, Helliwell PS, Husni ME, Love TJ, Lubrano E, McHugh N, Nash P, Ogdie A, Orbai AM, Parkinson A, O’Sullivan D, Rosen CF, Schwartzman S, Siegel EL, Toloza S, Tuong W, Ritchlin CT (2016) Group for Research and Assessment of Psoriasis and Psoriatic Arthritis 2015 treatment recommendations for psoriatic arthritis. Arthritis Rheumatol 68:1060–1071. https://doi.org/10.1002/art.39573

    Article  Google Scholar 

  10. Ogdie A, de Wit M, Callis Duffin K, Campbell W, Chau J, Coates LC, Eder L, Elmamoun M, FitzGerald O, Gladman DD, Goel N, James J, Kalyoncu U, Latella J, Lindsay C, Mease PJ, O’Sullivan D, Steinkoenig I, Strand V, Tillett W, Orbai AM (2017) Defining outcome measures for psoriatic arthritis: a report from the GRAPPA-OMERACT Working Group. J Rheumatol 44:697–700. https://doi.org/10.3899/jrheum.170150

    Article  PubMed  PubMed Central  Google Scholar 

  11. Fransen J, Antoni C, Mease PJ, Uter W, Kavanaugh A, Kalden JR, Van Riel PL (2006) Performance of response criteria for assessing peripheral arthritis in patients with psoriatic arthritis: analysis of data from randomised controlled trials of two tumour necrosis factor inhibitors. Ann Rheum Dis 65:1373–1378. https://doi.org/10.1136/ard.2006.051706

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  12. Gladman DD, Tom BD, Mease PJ, Farewell VT (2010) Informing response criteria for psoriatic arthritis. I: discrimination models based on data from 3 anti-tumor necrosis factor randomized studies. J Rheumatol 37:1892–1897. https://doi.org/10.3899/jrheum.091172

    Article  PubMed  Google Scholar 

  13. Eberl G, Studnicka-Benke A, Hitzelhammer H, Gschnait F, Smolen JS (2000) Development of a disease activity index for the assessment of reactive arthritis (DAREA). Rheumatology 39:148–155

    Article  CAS  PubMed  Google Scholar 

  14. Coates LC, Helliwell PS (2016) Defining low disease activity states in psoriatic arthritis using novel composite disease instruments. J Rheumatol 43:371–375. https://doi.org/10.3899/jrheum.150826

    Article  CAS  PubMed  Google Scholar 

  15. Coates LC, Fransen J, Helliwell PS (2010) Defining minimal disease activity in psoriatic arthritis: a proposed objective target for treatment. Ann Rheum Dis 69:48–53. https://doi.org/10.1136/ard.2008.102053

    Article  CAS  PubMed  Google Scholar 

  16. Helliwell PS, FitzGerald O, Fransen J, Gladman DD, Kreuger GG, Callis-Duffin K, McHugh N, Mease PJ, Strand V, Waxman R, Azevedo VF, Beltran Ostos A, Carneiro S, Cauli A, Espinoza LR, Flynn JA, Hassan N, Healy P, Kerzberg EM, Lee YJ, Lubrano E, Marchesoni A, Marzo-Ortega H, Porru G, Moreta EG, Nash P, Raffayova H, Ranza R, Raychaudhuri SP, Roussou E, Scarpa R, Song YW, Soriano ER, Tak PP, Ujfalussy I, de Vlam K, Walsh JA (2013) The development of candidate composite disease activity and responder indices for psoriatic arthritis (GRACE project). Ann Rheum Dis 72:986–991. https://doi.org/10.1136/annrheumdis-2012-201341

    Article  PubMed  Google Scholar 

  17. Kavanaugh A, van der Heijde D, Beutler A, Gladman D, Mease P, Krueger GG, McInnes IB, Helliwell P, Coates LC, Xu S (2016) Radiographic progression of patients with psoriatic arthritis who achieve minimal disease activity in response to golimumab therapy: results through 5 years of a randomized, placebo-controlled study. Arthritis Care Res (Hoboken) 68:267–274. https://doi.org/10.1002/acr.22576

    Article  CAS  Google Scholar 

  18. Taylor W, Gladman D, Helliwell P, Marchesoni A, Mease P, Mielants H, Group CS (2006) Classification criteria for psoriatic arthritis: development of new criteria from a large international study. Arthritis Rheum 54:2665–2673. https://doi.org/10.1002/art.21972

    Article  Google Scholar 

  19. Husted JA, Gladman DD, Farewell VT, Long JA, Cook RJ (1997) Validating the SF-36 health survey questionnaire in patients with psoriatic arthritis. J Rheumatol 24:511–517

    CAS  PubMed  Google Scholar 

  20. McKenna SP, Doward LC, Whalley D, Tennant A, Emery P, Veale DJ (2004) Development of the PsAQoL: a quality of life instrument specific to psoriatic arthritis. Ann Rheum Dis 63:162–169

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  21. Fries JF, Spitz P, Kraines RG, Holman HR (1980) Measurement of patient outcome in arthritis. Arthritis Rheum 23:137–145

    Article  CAS  Google Scholar 

  22. Zigmond AS, Snaith RP (1983) The hospital anxiety and depression scale. Acta Psychiatr Scand 67:361–370

    Article  CAS  Google Scholar 

  23. Fredriksson T, Pettersson U (1978) Severe psoriasis–oral therapy with a new retinoid. Dermatologica 157:238–244

    Article  CAS  PubMed  Google Scholar 

  24. Coates LC, Helliwell PS (2010) Validation of minimal disease activity criteria for psoriatic arthritis using interventional trial data. Arthritis Care Res (Hoboken) 62:965–969. https://doi.org/10.1002/acr.20155

    Article  Google Scholar 

  25. Schoels M, Aletaha D, Funovits J, Kavanaugh A, Baker D, Smolen JS (2010) Application of the DAREA/DAPSA score for assessment of disease activity in psoriatic arthritis. Ann Rheum Dis 69:1441–1447. https://doi.org/10.1136/ard.2009.122259

    Article  PubMed  Google Scholar 

  26. Prevoo ML, van ‘t Hof MA, Kuper HH, van Leeuwen MA, van de Putte LB, van Riel PL (1995) Modified disease activity scores that include twenty-eight-joint counts. Development and validation in a prospective longitudinal study of patients with rheumatoid arthritis. Arthritis Rheum 38:44–48

    Article  CAS  Google Scholar 

  27. Gladman DD, Mease PJ, Healy P, Helliwell PS, Fitzgerald O, Cauli A, Lubrano E, Krueger GG, van der Heijde D, Veale DJ, Kavanaugh A, Nash P, Ritchlin C, Taylor W, Strand V (2007) Outcome measures in psoriatic arthritis. J Rheumatol 34:1159–1166

    PubMed  Google Scholar 

  28. Schoels MM, Aletaha D, Alasti F, Smolen JS (2016) Disease activity in psoriatic arthritis (PsA): defining remission and treatment success using the DAPSA score. Ann Rheum Dis 75:811–818. https://doi.org/10.1136/annrheumdis-2015-207507

    Article  PubMed  Google Scholar 

  29. Mease PJ, Coates LC (2018) Considerations for the definition of remission criteria in psoriatic arthritis. Semin Arthritis Rheum 47:786–796. https://doi.org/10.1016/j.semarthrit.2017.10.021

    Article  PubMed  Google Scholar 

  30. Coates LC, FitzGerald O, Merola JF, Smolen J, van Mens LJJ, Bertheussen H, Boehncke WH, Callis Duffin K, Campbell W, de Wit M, Gladman D, Gottlieb A, James J, Kavanaugh A, Kristensen LE, Kvien TK, Luger T, McHugh N, Mease P, Nash P, Ogdie A, Rosen CF, Strand V, Tillett W, Veale DJ, Helliwell PS (2018) Group for Research and Assessment of Psoriasis and Psoriatic Arthritis/Outcome Measures in Rheumatology consensus-based recommendations and research agenda for use of composite measures and treatment targets in psoriatic arthritis. Arthritis Rheumatol 70:345–355. https://doi.org/10.1002/art.40391

    Article  PubMed  Google Scholar 

  31. Desthieux C, Granger B, Balanescu AR, Balint P, Braun J, Canete JD, Heiberg T, Helliwell PS, Kalyoncu U, Kvien TK, Kiltz U, Niedermayer D, Otsa K, Scrivo R, Smolen J, Stamm TA, Veale DJ, de Vlam K, de Wit M, Gossec L (2017) Determinants of patient–physician discordance in global assessment in psoriatic arthritis: a multicenter European Study. Arthritis Care Res (Hoboken) 69:1606–1611. https://doi.org/10.1002/acr.23172

    Article  Google Scholar 

  32. van Mens LJJ, Turina MC, van de Sande MGH, Nurmohamed MT, van Kuijk AWR, Baeten DLP (2018) Residual disease activity in psoriatic arthritis: discordance between the rheumatologist’s opinion and minimal disease activity measurement. Rheumatology (Oxford) 57:283–290. https://doi.org/10.1093/rheumatology/kex183

    Article  Google Scholar 

  33. Husted JA, Gladman DD, Farewell VT, Cook RJ (2001) Health-related quality of life of patients with psoriatic arthritis: a comparison with patients with rheumatoid arthritis. Arthritis Rheum 45:151–158. https://doi.org/10.1002/1529-0131(200104)45:2%3C151::AID-ANR168%3E3.0.CO;2-T

    Article  CAS  PubMed  Google Scholar 

  34. Husted JA, Tom BD, Schentag CT, Farewell VT, Gladman DD (2009) Occurrence and correlates of fatigue in psoriatic arthritis. Ann Rheum Dis 68:1553–1558. https://doi.org/10.1136/ard.2008.098202

    Article  CAS  PubMed  Google Scholar 

  35. Husni ME, Merola JF, Davin S (2017) The psychosocial burden of psoriatic arthritis. Semin Arthritis Rheum 47:351–360. https://doi.org/10.1016/j.semarthrit.2017.05.010

    Article  PubMed  Google Scholar 

  36. Freire M, Rodriguez J, Moller I, Valcarcel A, Tornero C, Diaz G, Armendariz Y, Paredes S (2011) Prevalence of symptoms of anxiety and depression in patients with psoriatic arthritis attending rheumatology clinics. Reumatol Clin 7:20–26. https://doi.org/10.1016/j.reuma.2010.03.003

    Article  PubMed  Google Scholar 

  37. van Mens LJJ, van de Sande MGH, Fluri IA, Atiqi S, van Kuijk AWR, Baeten DLP (2017) Residual disease activity and treatment adjustments in psoriatic arthritis in current clinical practice. Arthritis Res Ther 19:226. https://doi.org/10.1186/s13075-017-1424-8

    Article  PubMed  PubMed Central  Google Scholar 

  38. Marin J, Acosta Felquer ML, Ferreyra Garrot L, Ruta S, Rosa J, Soriano ER (2016) Patients with psoriatic arthritis fulfilling the minimal disease activity criteria do not have swollen and tender joints, but have active skin. J Rheumatol 43:907–910. https://doi.org/10.3899/jrheum.151101

    Article  PubMed  Google Scholar 

  39. van Mens LJJ, van de Sande MGH, van Kuijk AWR, Baeten D, Coates LC (2018) Ideal target for psoriatic arthritis? Comparison of remission and low disease activity states in a real-life cohort. Ann Rheum Dis 77:251–257. https://doi.org/10.1136/annrheumdis-2017-211998

    Article  PubMed  Google Scholar 

  40. Kane D, Stafford L, Bresnihan B, FitzGerald O (2003) A prospective, clinical and radiological study of early psoriatic arthritis: an early synovitis clinic experience. Rheumatology 42:1460–1468. https://doi.org/10.1093/rheumatology/keg384

    Article  CAS  PubMed  Google Scholar 

  41. Mease PJ, Ory P, Sharp JT, Ritchlin CT, Van den Bosch F, Wellborne F, Birbara C, Thomson GT, Perdok RJ, Medich J, Wong RL, Gladman DD (2009) Adalimumab for long-term treatment of psoriatic arthritis: 2-year data from the Adalimumab Effectiveness in Psoriatic Arthritis Trial (ADEPT). Ann Rheum Dis 68:702–709. https://doi.org/10.1136/ard.2008.092767

    Article  CAS  PubMed  Google Scholar 

  42. Kavanaugh A, McInnes I, Mease P, Krueger GG, Gladman D, Gomez-Reino J, Papp K, Zrubek J, Mudivarthy S, Mack M, Visvanathan S, Beutler A (2009) Golimumab, a new human tumor necrosis factor alpha antibody, administered every four weeks as a subcutaneous injection in psoriatic arthritis: twenty-four-week efficacy and safety results of a randomized, placebo-controlled study. Arthritis Rheum 60:976–986. https://doi.org/10.1002/art.24403

    Article  CAS  PubMed  Google Scholar 

  43. Feletar M, Brockbank JE, Schentag CT, Lapp V, Gladman DD (2004) Treatment of refractory psoriatic arthritis with infliximab: a 12-month observational study of 16 patients. Ann Rheum Dis 63:156–161

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  44. Haddad A, Thavaneswaran A, Ruiz-Arruza I, Pellett F, Chandran V, Cook RJ, Gladman DD (2015) Minimal disease activity and anti-tumor necrosis factor therapy in psoriatic arthritis. Arthritis Care Res (Hoboken) 67:842–847. https://doi.org/10.1002/acr.22529

    Article  CAS  Google Scholar 

  45. Overman CL, Kool MB, Da Silva JA, Geenen R (2016) The prevalence of severe fatigue in rheumatic diseases: an international study. Clin Rheumatol 35:409–415. https://doi.org/10.1007/s10067-015-3035-6

    Article  PubMed  Google Scholar 

  46. Sokoll KB, Helliwell PS (2001) Comparison of disability and quality of life in rheumatoid and psoriatic arthritis. J Rheumatol 28:1842–1846

    CAS  PubMed  Google Scholar 

  47. Wervers K, Vis M, Tchetverikov I, Gerards AH, Kok MR, Appels CWY, van der Graaff WL, van Groenendael J, Korswagen LA, Veris-van Dieren JJ, Hazes JMW, Luime JJ, The behalf of C (2018) Burden of psoriatic arthritis in different definitions of disease activity: comparing minimal disease activity and disease activity index for psoriatic arthritis. Arthritis Care Res (Hoboken). https://doi.org/10.1002/acr.23571

    Article  Google Scholar 

  48. McDonough E, Ayearst R, Eder L, Chandran V, Rosen CF, Thavaneswaran A, Gladman DD (2014) Depression and anxiety in psoriatic disease: prevalence and associated factors. J Rheumatol 41:887–896. https://doi.org/10.3899/jrheum.130797

    Article  PubMed  Google Scholar 

  49. Kavanaugh A, Fransen J (2006) Defining remission in psoriatic arthritis. Clin Exp Rheumatol 24(6 Suppl 43):S–S83

    CAS  PubMed  Google Scholar 

  50. Brikman S, Furer V, Wollman J, Borok S, Matz H, Polachek A, Elalouf O, Sharabi A, Kaufman I, Paran D, Elkayam O (2016) The effect of the presence of fibromyalgia on common clinical disease activity indices in patients with psoriatic arthritis: a cross-sectional study. J Rheumatol 43:1749–1754. https://doi.org/10.3899/jrheum.151491

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Physical Medicine and Rehabilitation, Afyon Kocatepe University Faculty of Medicine, Afyonkarahisar, Turkey

    Gamze Kilic

  2. Afyonkarahisar State Hospital, Rhematology Clinic, Afyonkarahisar, Turkey

    Erkan Kilic

  3. Division of Rheumatology and Immunology, Department of Physical Medicine and Rehabilitation, Sakarya University Faculty of Medicine, Sakarya, Turkey

    Kemal Nas, Ayhan Kamanlı & İbrahim Tekeoglu

Authors
  1. Gamze Kilic
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Erkan Kilic
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Kemal Nas
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Ayhan Kamanlı
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. İbrahim Tekeoglu
    View author publications

    You can also search for this author in PubMed Google Scholar

Contributions

GK is a corresponder author who has made substantial contribution to conception, design, interpretation of data and publication process. She has also participated in the review, drafting, and final approval of the manuscript. EK has made substantial contributions to the design, analysis and interpretation of data. He has drafted the manuscript for important intellectual content and also participated in final approval of the manuscript. KN has made substantial contributions to acquisition of data and drafting the article. He has approved the final version of the manuscript. AK has made substantial contributions to acquisition of data, drafting the article and approved the final version of the manuscript. İT has made substantial contributions to acquisition of data, revised article critically for important intellectual content and approved the final version of the manuscript.

Corresponding author

Correspondence to Gamze Kilic.

Ethics declarations

Conflict of interest

We have no conflicts of interest with respect to the authorship and/or publication of this article.

Ethical approval

All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.

Informed consent

All subjects in this study have been informed for the study protocol and written informed consents have been obtained.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Kilic, G., Kilic, E., Nas, K. et al. Residual symptoms and disease burden among patients with psoriatic arthritis: is a new disease activity index required?. Rheumatol Int 39, 73–81 (2019). https://doi.org/10.1007/s00296-018-4201-3

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00296-018-4201-3

Keywords

Search

Navigation